Relapsed/Refractory Non-Hodgkin Lymphoma - Phase 2

Trial Radar AI Trial Candidate or Patient Patient Caregiver Healthcare Pro Biotech Pro Biotech Investor Researcher Other
	Showing clinical trials for Relapsed/Refractory Non-Hodgkin Lymphoma. I can help you find clinical trials in specific locations and provide insights on health conditions and treatments. With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Showing clinical trials for Relapsed/Refractory Non-Hodgkin Lymphoma.

I can help you find clinical trials in specific locations and provide insights on health conditions and treatments.

With advanced mode, access powerful pre-screening tools, interactive data visualizations, customized email alerts for trial updates and more.

Study Title	Status
Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05768529	Recruiting
A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas NCT06090539	Recruiting
A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL NCT06484920	Recruiting
Study of CART Cell (MB-CART19.1) in Patients With Relapsed or Refractory CD19 Positive NHL NCT07271121	Recruiting
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). NCT05260957	Recruiting
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma NCT06845241	Not yet recruiting
Brentuximab Vedotin With or Without Nivolumab in Treating Patients With Relapsed or Refractory CD30+ Lymphoma NCT01703949	Active, not recruiting
An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma NCT03533283	Active, not recruiting
AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. (PRIMAVERA) NCT06137144	Recruiting
Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma NCT06088654	Recruiting
A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma NCT05623982	Recruiting
RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy NCT04827862	Active, not recruiting
Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma NCT07125872	Recruiting
AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma NCT04673617	Active, not recruiting
Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma NCT04586478	Recruiting
To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) (CAR-T for NHL) NCT06698484	Recruiting
Study of LYL314 in Aggressive Large B-Cell Lymphoma NCT05826535	Recruiting
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) NCT03930953	Active, not recruiting
Linperlisib Combination With Cyclophosphamide, Prednisone, and Thalidomide (CPT) in R/R NHL NCT07195799	Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas NCT02259556	Recruiting
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma NCT05950165	Recruiting
A Study of GNC-035 in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies NCT06066203	Recruiting
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL) (TRANSCEND FL) NCT04245839	Active, not recruiting
Efficacy and Safety of Zanubrutinib, Rituximab, and Lenalidomide (ZR²) in Combination With Tislelizumab for Relapsed/Refractory Follicular Lymphoma NCT07418190	Recruiting
Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT07159906	Not yet recruiting
Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma NCT07477366	Not yet recruiting
Study of Cord Blood-derived CAR NK Cells Targeting CD19/CD70 in Refractory/Relapsed B-cell Non-Hodgkin Lymphoma NCT05842707	Recruiting
A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FL NCT07031700	Not yet recruiting
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma NCT06806033	Recruiting
A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL NCT05806099	Recruiting
Chidamide Combined With Linperlisibon for the Treatment of Refractory/Relapsed Follicular Lymphoma NCT06158386	Recruiting
Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL NCT05554939	Recruiting
Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma NCT03015896	Active, not recruiting
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3) NCT06035497	Recruiting
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (STARLIGHT-1) NCT06343311	Recruiting
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01) NCT06534437	Recruiting
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma NCT06323525	Recruiting
A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma NCT04077723	Active, not recruiting
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy (REFRACT) NCT05848765	Recruiting
A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma NCT07439653	Not yet recruiting
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma (Glo-BNHL) NCT05991388	Recruiting
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas NCT06300528	Recruiting
Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma NCT05338931	Recruiting
Azacytidine Plus CAOLD Regimen in Relapsed/Refractory Peripheral T-Cell Lymphomas NCT06176027	Recruiting
Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma NCT06826118	Recruiting
Safety and Efficacy of EX103 in Subjects with Relapsed/Refractory CD20-Positive Non-Hodgkin Lymphoma NCT06021678	Recruiting
TRAC and Power3 (SPPL3) Genes Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-NHL NCT06014073	Recruiting
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies NCT05880043	Recruiting
Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (ACIT001/EXC002) NCT03938987	Recruiting
Epco, Zanu, Ritux for R/R FL or MZL NCT06563596	Recruiting

Clinical Trial Radar

Phase

Type

Study Type

Age Group

Biological Sex

Placebo

Phase

Type

Study Type

Age Group

Biological Sex